The global cancer biomarkers market is projected to grow from $28.25 billion in 2026 to $54.48 billion by 2032, at an 11.6% CAGR. Growth is fueled by rising cancer rates, technological advances like multi-omics and AI integration, and increased demand for early, precise diagnostics. Asia-Pacific is the fastest-growing region due to healthcare infrastructure expansion and rising cancer incidence. Key players include Roche, Thermo Fisher, and Illumina, with diagnostic labs leading end-user demand. Challenges include high costs, regulatory hurdles, and technical complexities, but opportunities arise from personalized medicine and liquid biopsy innovations.
ResearchAndMarkets.com released a comprehensive report analyzing over 1,230 bioinformatics collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, including upfront payments, milestones, royaltie...
Illumina announced that Formation Bio has joined the Billion Cell Atlas alliance, which uses large-scale genome-wide perturbation data to advance AI-driven drug discovery. The Atlas, launched in January 2026, sequences over 350 million cells to map d...
